Teva Pharmaceutical Industries (TEVA) Divestments (2020 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Divestments for 7 consecutive years, with $42.0 million the latest figure, recorded in Q1 2026.

• Quarterly Divestments rose 147.06% year-over-year to $42.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.0 million (down 1.67% YoY) and the FY2025 annual result came in at $34.0 million, down 20.93% from the prior year.
• Divestments rose to $42.0 million in Q1 2026 per TEVA's latest filing, from $8.0 million in the prior quarter.
• Over the last five years, Divestments for TEVA reached as high as $56.0 million in Q2 2023 and fell as low as $1.0 million in Q2 2024.
• A 5-year average of $18.2 million and a median of $13.5 million in 2023 frame the typical range for Divestments.
• Annual changes were most pronounced in 2024 — Divestments slumped 98.21% — and 2025, when it soared 800.0%.
• Year by year, Divestments stood at $23.0 million in 2022, then sank by 56.52% to $10.0 million in 2023, then tumbled by 60.0% to $4.0 million in 2024, then surged by 100.0% to $8.0 million in 2025, then surged by 425.0% to $42.0 million in 2026.
• According to Business Quant data, Divestments over the past three periods registered $42.0 million, $8.0 million, and $9.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.